Can You Take Repatha (Evolocumab) With Benzodiazepines?

Why This Drug Combination Raises Questions

Patients prescribed Repatha (evolocumab) for familial hypercholesterolemia or atherosclerotic cardiovascular disease (ASCVD) often take multiple medications. Anxiety, insomnia, and muscle spasm are common comorbidities that lead to benzodiazepine prescriptions, so the question of whether these two drug classes interact comes up frequently in clinical practice.

The short answer: evolocumab does not interact with benzodiazepines through any known mechanism. But "no interaction" still deserves a detailed explanation, because the reasoning behind that conclusion matters for prescribers making real-time formulary decisions. The pharmacokinetic profiles of monoclonal antibodies and small-molecule sedatives are so different that overlap is biochemically implausible. The FOURIER trial (N=27,564) tracked adverse events across a broad polypharmacy population for a median of 2.2 years and reported no signal suggesting CNS-related harm from evolocumab co-administration with other drug classes [1]. The Repatha FDA prescribing information does not list any drug-drug interactions at all, a reflection of the antibody's non-hepatic clearance route [2].

How Evolocumab Is Metabolized

Evolocumab is a fully human IgG2 monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). Its elimination follows the pathway common to all therapeutic antibodies: target-mediated disposition at low concentrations and nonspecific proteolytic degradation by the reticuloendothelial system at therapeutic doses [2].

This distinction is fundamental. Small-molecule drugs are typically oxidized by hepatic cytochrome P450 (CYP) enzymes, conjugated by UDP-glucuronosyltransferases, or transported by efflux pumps like P-glycoprotein (P-gp). Monoclonal antibodies bypass all of these systems entirely. They are too large (approximately 144 kDa for IgG2) to serve as substrates for CYP enzymes, and they do not enter hepatocytes through conventional uptake transporters [3]. A 2020 review in Clinical Pharmacology & Therapeutics confirmed that no approved monoclonal antibody has demonstrated clinically relevant CYP-mediated drug-drug interactions in controlled studies [3].

The Repatha prescribing information reflects this biology directly. Section 7 (Drug Interactions) contains no listed interactions, and population pharmacokinetic analyses of FOURIER data showed no effect of concomitant statin therapy, ezetimibe, or other cardiovascular drugs on evolocumab clearance [2]. The antibody behaves identically whether it is the only medication a patient takes or one of fifteen.

How Benzodiazepines Are Metabolized

Benzodiazepines, by contrast, are classic small-molecule hepatic substrates. Their metabolic routes vary by agent, and this variation matters clinically.

CYP3A4-dependent benzodiazepines include alprazolam, midazolam, and triazolam. These agents are sensitive to CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) and inducers (rifampin, carbamazepine, phenytoin), which can raise or lower plasma concentrations significantly [4]. A well-known example: co-administration of ketoconazole with midazolam increases midazolam AUC by approximately 15-fold [4].

CYP2C19-dependent benzodiazepines include diazepam, which undergoes N-demethylation to nordazepam through CYP2C19 and CYP3A4. Poor metabolizers of CYP2C19 (roughly 2-5% of Caucasian and 15-20% of Asian populations) show prolonged diazepam half-life [5].

Glucuronidation-only benzodiazepines include lorazepam, oxazepam, and temazepam. These skip Phase I oxidation entirely and are conjugated directly by UGT enzymes. They carry the fewest drug interaction risks within the class and are often preferred in patients on complex regimens [4].

None of these pathways intersect with evolocumab's proteolytic clearance. A CYP inhibitor can double alprazolam levels. A monoclonal antibody cannot.

Pharmacodynamic Considerations

Beyond metabolism, pharmacodynamic (PD) interactions occur when two drugs affect the same physiological system. Benzodiazepines enhance GABAergic inhibition in the central nervous system, producing sedation, anxiolysis, and muscle relaxation. The risks of PD interactions with benzodiazepines center on additive CNS depression when combined with opioids, alcohol, other sedative-hypnotics, or certain antihistamines [4].

Evolocumab acts exclusively in the peripheral circulation. It binds free PCSK9, prevents PCSK9-mediated degradation of LDL receptors on hepatocyte surfaces, and increases LDL-C clearance from plasma [2]. The drug does not cross the blood-brain barrier in meaningful quantities, does not bind CNS receptors, and does not modulate neurotransmitter systems. In FOURIER, neurocognitive adverse events (assessed by the EBBINGHAUS substudy, N=1,974) occurred at identical rates in the evolocumab and placebo groups, with no difference in spatial working memory, working memory strategy, or reaction time over a median of 19 months [6].

This means there is no pharmacodynamic basis for additive sedation, respiratory depression, or cognitive impairment when combining Repatha with any benzodiazepine.

What the Clinical Trial Data Show

The FOURIER trial remains the definitive cardiovascular outcomes study for evolocumab. Published in the New England Journal of Medicine in 2017, FOURIER randomized 27,564 patients with established ASCVD to evolocumab 140 mg every 2 weeks (or 420 mg monthly) versus placebo, on top of optimized statin therapy [1].

Key safety findings relevant to this combination:

Evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% (HR 0.85, 95% CI 0.79-0.92, P<0.001) [1]. The adverse event profile was notable for its similarity to placebo. Injection-site reactions occurred in 2.1% of the evolocumab group versus 1.6% on placebo. Myalgia rates were equivalent. There was no excess of hepatotoxicity, rhabdomyolysis, or new-onset diabetes [1].

Concomitant medication use in FOURIER was extensive. Over 90% of participants took statins, roughly 30% took ezetimibe, and the population reflected real-world polypharmacy including antihypertensives, antiplatelets, anticoagulants, and psychotropic medications. No subgroup analysis identified an interaction signal with any co-administered drug class [1].

The OSLER-1 extension study followed evolocumab-treated patients for up to 5 years and confirmed persistent LDL-C lowering (mean achieved LDL-C of 30 mg/dL) with no late-emerging safety signals [7]. The consistency of this data across tens of thousands of patient-years provides strong evidence that evolocumab does not participate in clinically relevant drug interactions.

Monitoring Recommendations for Patients on Both Drugs

No interaction-specific monitoring is required. Standard monitoring for each drug individually still applies.

For evolocumab: check a fasting lipid panel 4 to 8 weeks after initiation or dose change to confirm LDL-C response. The 2018 AHA/ACC cholesterol guideline recommends reassessing adherence and LDL-C levels annually in patients on PCSK9 inhibitors [8]. Injection-site reactions should be assessed at follow-up visits.

For benzodiazepines: monitor for sedation, cognitive impairment, and fall risk, especially in patients over age 65. The American Geriatrics Society 2023 Beers Criteria lists all benzodiazepines as potentially inappropriate in older adults due to increased risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes [9]. If a patient on both drugs reports new sedation or dizziness, the benzodiazepine (or another CNS-active co-medication) is the place to look. Evolocumab is not the cause.

Liver function monitoring deserves a specific note. Benzodiazepines are hepatically cleared, and patients with hepatic impairment may require dose reduction of CYP3A4-dependent agents like alprazolam [4]. Evolocumab does not affect hepatic function. In FOURIER, ALT elevations greater than 3 times the upper limit of normal occurred at identical rates in evolocumab and placebo arms [1].

Practical Prescribing Guidance

For prescribers evaluating whether to co-prescribe Repatha and a benzodiazepine, the clinical decision framework is straightforward.

Step one: confirm the indication for each drug independently. Evolocumab is indicated for heterozygous or homozygous familial hypercholesterolemia or established ASCVD when LDL-C remains above goal on maximally tolerated statin therapy [2]. The benzodiazepine indication (anxiety, insomnia, seizure, procedural sedation, muscle spasm) should meet its own evidence threshold.

Step two: select the benzodiazepine based on the patient's hepatic function, age, and other co-medications. Patients on CYP3A4 inhibitors (common in cardiovascular populations, such as diltiazem or amiodarone) may benefit from a glucuronidated agent like lorazepam to avoid stacking CYP3A4 interactions [4]. This decision has nothing to do with evolocumab. It reflects standard benzodiazepine prescribing.

Step three: document that no dose adjustment of either drug is needed for the combination. The FDA label for Repatha supports this directly [2].

Step four: counsel the patient. Many patients receiving injectable biologics worry about drug interactions, and reassurance backed by mechanistic explanation improves adherence. Explaining that "Repatha is a protein broken down by your immune system, not by your liver, so it doesn't compete with your other medications for the same processing pathway" is both accurate and accessible.

When to Reconsider the Combination

The absence of a drug-drug interaction does not mean both prescriptions are automatically appropriate. Two clinical scenarios warrant reassessment.

First, if a patient on evolocumab develops statin-related myopathy and discontinues their statin, the net cardiovascular benefit calculation changes. PCSK9 inhibitor monotherapy reduces LDL-C by approximately 60%, but the evidence base for outcomes benefit is built on the PCSK9 inhibitor-plus-statin combination [1]. A patient whose anxiety or insomnia is severe enough to require benzodiazepines may have autonomic or stress-related contributors to cardiovascular risk that merit broader evaluation.

Second, benzodiazepine use in older adults with ASCVD carries independent risks. Falls in patients on anticoagulants or dual antiplatelet therapy can result in serious bleeding. The 2019 ACC/AHA primary prevention guideline emphasizes fall-risk assessment in older adults on antithrombotic therapy [10]. If a clinician is reviewing the medication list of a 72-year-old on evolocumab, aspirin, a P2Y12 inhibitor, and lorazepam, the safety question is not about the evolocumab-benzodiazepine interaction. It is about the bleeding risk from a fall caused by sedation.

Special Populations

Hepatic impairment. Evolocumab pharmacokinetics are unaffected by mild to moderate hepatic impairment (Child-Pugh A and B). It has not been studied in severe hepatic impairment (Child-Pugh C) [2]. CYP3A4-metabolized benzodiazepines (alprazolam, midazolam, triazolam) require dose reduction or avoidance in hepatic impairment. Lorazepam and oxazepam are preferred in this population because glucuronidation is preserved until late-stage liver disease [4].

Renal impairment. Monoclonal antibodies are not renally cleared, and no dose adjustment of evolocumab is needed at any creatinine clearance [2]. Benzodiazepine metabolites (particularly active metabolites of diazepam and chlordiazepoxide) may accumulate in renal impairment, but this is a drug-specific concern unrelated to evolocumab co-administration.

Pregnancy. Evolocumab is classified as having insufficient human data; animal studies showed no fetal harm at exposures up to 30 times the human dose [2]. Most benzodiazepines carry FDA pregnancy category D labeling due to neonatal withdrawal risk and possible teratogenicity in the first trimester. The combination is unlikely in practice, but if it arises, each drug's pregnancy risk should be evaluated independently.

The Bottom Line on This Combination

Evolocumab and benzodiazepines occupy entirely separate pharmacological spaces. One is a 144 kDa protein cleared by proteolysis in the reticuloendothelial system. The other is a small molecule metabolized by hepatic CYP enzymes or glucuronidation. No CYP inhibition, no transporter competition, no receptor overlap, and no clinical trial signal of harm. Patients who need both drugs can take them together at standard doses with standard monitoring for each agent individually [1][2].